Part of the high risk types of human papillomavirus (HPV) are transmitted by sexual contact and lead to cervical,anal and other cancers.Two HPV vaccines,Gardasil quadrivalent vaccine and Cervarix bivalent vaccine,have been approved by FDA.Both vaccines have been widely used,but have not yet entered China.Researchers are committed to developing low-cost and broad-spectrum protective second-generation vaccines.This review focuses on current progress in development of the next generation prophylactic HPV vaccines.